Skip to main content

Advertisement

SpringerLink
Log in

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Background

Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. It is the S-enantiomer of citalopram, and is responsible for the serotonin reuptake activity, and thus for its pharmacological effects. Previous studies pointed out that clinically efficacious doses of other SSRIs produce an occupancy of the serotonin reuptake transporter (SERT) of about 80% or more. The novel radioligand [123I]ADAM and single photon emission computer tomography (SPECT) were used to measure midbrain SERT occupancies for different doses of escitalopram and citalopram.

Methods

Twenty-five healthy subjects received a single dose of escitalopram [5 mg (n=5), 10 mg (n=5), and 20 mg (n=5)] or citalopram [(10 mg (n=5) and 20 mg (n=5)]. Midbrain SERT binding was measured with [123I]ADAM and SPECT on two study days, once without study drug and once 6 h after single dose administration of the study drug. The ratio of midbrain-cerebellum/cerebellum was the outcome measure (V3”) for specific binding to SERT in midbrain. Subsequently, SERT occupancy levels were calculated using the untreated baseline level for each subject. An E max model was used to describe the relationship between S-citalopram concentrations and SERT occupancy values. Additionally, four subjects received placebo to determine test–retest variability.

Results

Single doses of 5, 10, or 20 mg escitalopram led to a mean SERT occupancy of 60±6, 64±6, and 75±5%, respectively. SERT occupancies for subjects treated with single doses of 10 and 20 mg citalopram were 65±10 and 70±6%, respectively. A statistically significant difference was found between SERT occupancies after application of 10 and 20 mg escitalopram, but not for 10 and 20 mg citalopram. There was no statistically significant difference between the SERT occupancies of either 10 mg citalopram or 10 mg escitalopram, or between 20 mg citalopram and 20 mg escitalopram. E max was slightly higher after administration of citalopram (84%) than escitalopram (79%). In the test–retest study, a mean SERT “occupancy” of 4% was found after administration of placebo, the intraclass correlation coefficient was 0.92, and the repeatability coefficient was 0.25.

Conclusion

SPECT and [123I]ADAM were used to investigate SERT occupancies after single doses of escitalopram or citalopram. The test–retest study revealed good reproducibility of SERT quantification. Similar SERT occupancies were found after administration of equal doses (in respect to mg) of escitalopram and citalopram, giving indirect evidence for a fractional blockade of SERT by the inactive R-citalopram.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Acton PD, Choi SR, Hou C, Plossl K, Kung HF (2001) Quantification of serotonin transporters in nonhuman primates using [123I]ADAM and SPECT. J Nucl Med 42(10):1556–1562

    PubMed  CAS  Google Scholar 

  • Alexopoulos GS, Privitera W, Ventura D, Bose A, Lenz SM, Wang Q (2004) Fixed dose of escitalopram (10 mg/day) and a flexible dosing regime of sertraline (50–200 mg/day) in a randomized, double-blind comparison in depressed patients. World J Biol Psychiatry 5(Suppl 1):97

    Google Scholar 

  • Backstrom I, Bergstrom M, Marcusson J (1989) High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486(2):261–268

    Article  PubMed  CAS  Google Scholar 

  • Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287–295

    CAS  Google Scholar 

  • Catafau AM, Perez V, Penengo MM, Bullich S, Danus M, Puigdemont D, Pascual JC, Corripio I, Llop J, Perich J, Alvarez E (2005) SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test–retest in healthy volunteers. J Nucl Med 46(8):1301–1309

    PubMed  CAS  Google Scholar 

  • Chen F, Larsen MB, Sanchez C, Wiborg O (2003) The S-enantiomer of citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 12:S217

    Google Scholar 

  • Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, Acton PD, Kung HF (2000) Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38(4):403–412

    Article  PubMed  CAS  Google Scholar 

  • Erlandsson KT, Sivananthan D Lui, Spezzi A, Townsend CE, Mu S, Lucas R, Warrington S, Ell PJ (2005) Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 32(11):1329–1336

    Article  PubMed  CAS  Google Scholar 

  • Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2000) Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 10(2):133–142

    Article  PubMed  CAS  Google Scholar 

  • Frokjaer VG, Pinborg LH, Madsen H, Knudsen GM (2004) Evaluation of the serotonin transporter ligand [123I]ADAM for SPECT studies in humans. Neuroimage 22(Suppl 2):T176

    Google Scholar 

  • Gorman JM, Kent JM (1999) SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(Suppl 4):33–38 (Discussion 39)

    PubMed  Google Scholar 

  • Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 7(4 Suppl):40–44

    PubMed  Google Scholar 

  • Kasper S (2004) Unique mechanism of action for escitalopram: does it hold the promise? Int J Psychiatry Clin Pract 8(Suppl 1):15–18

    Article  CAS  Google Scholar 

  • Kasper S, Heiden A (1995) Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 10:163–171

    Article  Google Scholar 

  • Kasper S, Vieira A, Schmidt R, Richter P (1990) Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiatry 23(2): 76–84

    Article  PubMed  CAS  Google Scholar 

  • Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brucke T (2002) Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette’s disorder–implications for psychopharmacology. World J Biol Psychiatry 3(3):133–146

    Article  PubMed  Google Scholar 

  • Kasper S, Spadone C, Verpillat P, Angst J (2006) Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 21(2):105–110

    Article  PubMed  Google Scholar 

  • Kauppinen TA, Bergstrom KA, Heikman P, Hiltunen J, Ahonen AK (2003) Biodistribution and radiation dosimetry of [123I]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med Mol Imaging 30(1):132–136

    Article  PubMed  CAS  Google Scholar 

  • Klein N, Sacher J, Mossaheb N, Asenbaum S, Pötzi C, Dobrozemsky G, Dudczak R, Kasper S, Tauscher J (2004) Quantification of serotonin transporters with [123I]ADAM and SPECT in healthy human subjects: preliminary data on tracer kinetics. Biol Psychiatry 55:S212

    Google Scholar 

  • Kugelberg F, Carlsson CB, Ahlner J, Bengtsson F (2003) Stereoselective single-dose kinetics of citalopram and its metabolites in rats. Chirality 15(7):622–629

    Article  PubMed  CAS  Google Scholar 

  • Larsen F, Priskorn M, Overo KF (2001) Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 41(3):340–346

    Article  PubMed  CAS  Google Scholar 

  • Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH (2004) Selectivity of 3H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141(6):1015–1023

    Article  PubMed  CAS  Google Scholar 

  • Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL et al (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13(4):295–309

    Article  PubMed  CAS  Google Scholar 

  • Lepola UM, Loft H (2003) Reines EH Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211–217

    Article  PubMed  Google Scholar 

  • Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100

    Article  PubMed  CAS  Google Scholar 

  • Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005) Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59(3):268–275

    Article  PubMed  CAS  Google Scholar 

  • Malling D, Poulsen MN, Sogaard B (2005) The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 60(3):287–290

    Article  PubMed  CAS  Google Scholar 

  • Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158(11):1843–1849

    Article  PubMed  CAS  Google Scholar 

  • Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S Links P (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160(1):90–99

    Article  PubMed  Google Scholar 

  • Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826–835

    Article  PubMed  Google Scholar 

  • Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M (2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88(5):282–286

    Article  PubMed  CAS  Google Scholar 

  • Moore N, Verdoux H, Fantino B (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20(3):131–137

    Article  PubMed  Google Scholar 

  • Mork A, Kreilgaard M, Sanchez C (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45(2):167–173

    Article  PubMed  CAS  Google Scholar 

  • Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24(3):589–591

    Article  PubMed  CAS  Google Scholar 

  • Oya S, Choi SR, Hou, Mu M, Kung MP, Acton PD, Siciliano M Kung HF (2000) 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27(3):249–254

    Article  PubMed  CAS  Google Scholar 

  • Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brucke T (1995) beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 100(3):247–256

    Article  PubMed  CAS  Google Scholar 

  • Rochat B, Baumann P, Audus KL (1999) Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831(1–2):229–236

    Article  PubMed  CAS  Google Scholar 

  • Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Pötzi C, Attarbaschi T, Lanzenberger R, Dudczak R, Kasper S, Tauscher J (2006) [123I]ADAM: a novel SPECT ligand for quantification of serotonin transporters in humans. Int J Neuropsychopharmacology (in press)

  • Sanchez C, Kreilgaard M (2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77(2):391–398

    Article  PubMed  CAS  Google Scholar 

  • Sanchez C, Gruca P, Bien E, Papp M (2003a) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75(4):903–907

    Article  PubMed  CAS  Google Scholar 

  • Sanchez C, Gruca P, Papp M (2003b) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14(5–6):465–470

    PubMed  CAS  Google Scholar 

  • Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004) Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174(2):163–176

    Article  CAS  Google Scholar 

  • Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9(7):686–692

    Article  PubMed  CAS  Google Scholar 

  • Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M Ebert B (2004) R-citalopram functionally antagonises scitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142(1):172–180

    Article  PubMed  CAS  Google Scholar 

  • Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brucke T, Kasper S (1999) In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol 9(1–2):177–179

    Article  PubMed  CAS  Google Scholar 

  • Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7(3):317–321

    Article  PubMed  CAS  Google Scholar 

  • Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, Tauscher J, Hilger E, Stastny J, Brucke T, Kasper S (2000) [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 47(6):482–489

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The study was supported by an unrestricted grant from H. Lundbeck A/S. The study was partially supported by the “Bürgermeisterfonds der Stadt Wien” PNr: 2180/03.

Author information

Authors and Affiliations

  1. Department of General Psychiatry, University Hospital for Psychiatry, Währinger Gürtel, 18-20A-1090, Vienna, Austria

    N. Klein, J. Sacher, T. Geiss-Granadia, T. Attarbaschi, N. Mossaheb, R. Lanzenberger, A. Holik, C. Spindelegger, J. Tauscher & S. Kasper

  2. Department of Clinical Neurology, Medical University of Vienna, Vienna, Austria

    S. Asenbaum

  3. Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

    C. Pötzi & R. Dudczak

Authors
  1. N. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Sacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Geiss-Granadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Attarbaschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Mossaheb
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Lanzenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Pötzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Holik
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Spindelegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Asenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Dudczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Tauscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S. Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Kasper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, N., Sacher, J., Geiss-Granadia, T. et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 188, 263–272 (2006). https://doi.org/10.1007/s00213-006-0486-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-006-0486-0

Keywords

Search

Navigation